Cyclophosphamide: Clinical Pharmacology, Uses and Potential Adverse Effects

Maher Salamoon (Editor)
Breast Cancer Department, Al-Bairouni University Cancer Center, Damascus, Syria

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$145.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

This text contains seven chapters, five of which are original articles. One of them deals with the invention and development of cyclophosphamide, mechanisms of action and side effects while a separate chapter deals with the management of hemorrhagic cystitis, the most important and serious side effect after using the drug at high doses.

Other chapters deal with the clinical application in metastatic breast cancer and the role of cyclophosphamide in improving breast cancer microenvironment through mobilization of mesenchymal stem cells from bone marrow. The idea of metronomic chemotherapy in combination with Aromatase inhibitors (AI) in breast cancer with bone metastasis is also explained in this book. Cyclophosphamide may replace Ifosfamide in case of an Ifosfamide shortage in metastatic soft tissue sarcoma. Finally, the drug that forms one of the back bones of the ACEP protocol used to treat the aggressive Peripheral T-cell non-Hodgkin’s lymphoma is described by the authors.
(Imprint: Nova Biomedical)

Preface

Editor Contact Information

Acknowledgement

Chapter 1 - Alkylating Agents (pp. 1-20)
Obeida Khalife, Muhammad Muhammad, Mazen Kenj and Maher Salamoon (Department of Medical Oncology; Kenj Cytogenetic Lab, and Department of Hematology, Al Bairouni University Cancer Center, Damascus, Syria)

Chapter 2 - Cyclophosphamide in Hematological Malignancies (pp. 21-56)
Saurabh Chhabra, Rishi Agarwal, Zartash Gul and Muneer H. Abidi (Medical University of South Carolina, Charleston SC, USA and others)

Chapter 3 - Treatment of Peripheral T-Cell Lymphoma with an Intensive Protocol ACEP (Adriamycin, Cyclophosfamide, Etoposide and Prednisolone) and Ifosfamide Showing a Good Overall Survival Rate at 7 Years (pp. 57-66)
Maher Salamoon, Marouane Bachour, Taisir Hussein and Mazen Kenj (Al Bairouni University Hospital, Department of Hematology and Medical Oncology; Tishreen Hospital, Department of Pathology, and Mazen Kenj Laboratory, Molecularbiology Section, Damascus, Syria)

Chapter 4 - Improving Cancer Micro-Environment in Breast Cancer with Bone Metastasis through Chemopriming with High-Dose Cyclophosphamide and Mesenchymal Stem Cells Mobilization (pp. 67-74)
Mazen Kenj and Maher Salamoon (Kenj Lab, and Department of Medical Oncology, Al Bairouni University Cancer Center, Damascus, Syria)

Chapter 5 - Oral Cyclophosphamide in Combination with Aromatase Inhibitors Can Control Bone Pain in Breast Cancer with Painful Bone Metastasis (pp. 75-84)
Maher Salamoon (Al Bairouni University Hospital, Damascus, Syria)

Chapter 6 - High-Dose Cyclophosphamide Can Replace Ifosfamide in Metastatic Soft Tissue Sarcoma in Case of Ifosfamide Shortage (pp. 85-94)
Maher Salamoon (Al Bairouni University Hospital, Damascus, Syria)

Chapter 7 - Cyclophosphamide–Induced Hemorrhagic Cystitis (pp. 95-122)
Muhammad Muhammad, Obeida Khalife, Mazen Kenj and Maher Salamoon (Department of Medical Oncology, Al Bairouni University Cancer Center, and Kenj Cytogenetic Lab, Damascus, Syria)

Index

Audience: For medical schools students, basic researchers, hematologists and oncologists

You have not viewed any product yet.